Company Overview and News
RIO DE JANEIRO, BRAZIL – One of the most drawn out behind-the-scenes football (soccer) storylines in recent memory may have finally reached its conclusion late Wednesday (April 5th) as local news reports that French media company, Lagardère, has reached an agreement in principle with Odebrecht to take over operations of the iconic Maracanã Stadium.
RIO DE JANEIRO, BRAZIL – In a surprising move, local news reported late Wednesday, February 22nd, that the multi-national consortium comprised of CSM (Chime Sports Marketing), GL Events and Amsterdam Arenas, one of only two groups in the running to take over management of the iconic Maracanã Stadium, has taken itself out of the running.
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report presents the analysis of the global Exhibition Industry market on the basis of value and by rented space for the Regions (USA, Europe, APAC, ROW) and for Countries (USA, UK, Germany, France , China, India, Hong Kong, Brazil).
SÃO PAULO, 21 de noviembre de 2016 /PRNewswire/ -- "Vine aquí con la humildad que caracteriza al pueblo uruguayo, a invitar a los empresarios brasileños a invertir en nuestro país", enfatizó el presidente uruguayo Tabaré Vázquez en ocasión del almuerzo-debate organizado por el LIDE – Grupo de Líderes Empresariales, este lunes (21), en el hotel Grand Hyatt de São Paulo. Vázquez destacó que su gobierno trabaja por la integración regional, junto a socios como Brasil, sin renunciar a la posición de Uruguay en el mundo globalizado.
(ANSA) - Turin, September 23 - Two executives at Turin trade fair and exhibition center Lingotto Fiere and an official from the Turin Foundation for Books, Music and Culture on Friday plea bargained a suspended sentence of one year in prison for bid-rigging. Lingotto Fiere Managing Director Regis Faure, Marketing Director Roberto Fantino and Foundation secretary Valentino Macri were accused of steering the contract to organize the 29th Turin International Book Fair, which was held in May this year.
(ANSA) - Turin, July 12 - Former Turin city cabinet member in charge of culture Maurizio Braccialarghe was placed under investigation Tuesday as part of a corruption probe into the city's annual international book fair, which was last held in May. Carabinieri police conducted a search of his premises. Four people were arrested earlier on suspicion of bid-rigging in relation to a probe into the organisation of fair.
(ANSA) - Turin, July 12 - Four people were arrested on Tuesday on suspicion of bid-rigging in relation to a probe into the organisation of the Turin book fair in May this year. An official of the Book Foundation and two managers of the company Gl Events were taken to in prison, while a representative of the Bologna trade fair company was placed under house arrest. A search was also ordered against former city cabinet member for culture Maurizio Braccialarghe, sources said.
LYON, FRANCE--(Marketwired - Feb 18, 2016) - From February 8 to 12, 20 candidates selected within the BigBooster program attended a boot camp in Boston, in partnership with Mass Challenge. Ten candidates selected at the end of boot camp will participate in the final selection at Biovision in Lyon-France (April...
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...